UroGen Pharma Ltd. (URGN)
Nasdaq · Healthcare · Biotechnology
$42.78+3.33%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.1B
- Forward P/E
- 15.3
- 52-week range
- $15.86 – $50.81
- 52-week change
- +142.82%
- EPS (trailing)
- −$1.97
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $110M (+21.45%)
- Net income
- −$153M
- Operating margin
- −113.7%
- Free cash flow
- −$163M
From the company’s annual report on SEC EDGAR.
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc.
Headquarters: Princeton, United States · 300 employees · urogen.com